Roivant Sciences Ltd.
http://roivant.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Roivant Sciences Ltd.
Pharma Happy To Be Custodian For Innovative Science From Cash-Strapped Biotechs
C-suite leaders from Lilly, Roche and J&J spoke at a Citeline-sponsored panel at Swiss Biotech Day in Basel and offered encouragement to start-ups trying to negotiate the tricky financial landscape.
Roivant May Take On AbbVie In Uveitis With Strong Phase II Efficacy
Roivant’s brepocitinib bests data Humira previously posted in non-infectious uveitis, a top cause of blindness. The TYK2/JAK1 inhibitor also is in Phase III for dermatomyositis.
Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies
Plus deals involving BioVaxys/IMV, Immunome/Ayala, Nascent/Manhattan BioSolutions, AVROBIO/Tectonic, Sanofi/Synthekine, NAYA/Florida Biotechnologies as well as deals in brief and tech transfer agreements.
Roivant Shopping For Multiple, Transformative Deals
The company is looking to spend some of the cash it earned on the sale of Telavant on new assets that will join the late-stage pipeline.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice